Peptides for Recovery
Comprehensive guide to 2 peptides researched for recovery, ranked by evidence strength from FDA-approved to early preclinical. Each compound is evaluated on mechanism, clinical status, and safety profile.
Overview
2 research peptides are currently studied for recovery. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Somatropin (rHGH) — FDA-Approved
Evidence Rating: A
Category: Growth Hormone
Somatropin is recombinant human growth hormone (rHGH), a 191-amino-acid protein identical to naturally produced pituitary GH. Unlike secretagogues (which stimulate GH release), somatropin IS the direct hormone. FDA-approved for multiple indications including growth hormone deficiency, Turner syndrom...
Key claims: Treats growth hormone deficiency; Promotes linear growth in GH-deficient children.
CJC-1295 with DAC — Phase I-II data; research compound
Evidence Rating: C
Category: Growth Hormone
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone-releasing hormone (GHRH) analog with a unique lysine-linked maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo. This albumin binding extends the half-life from minutes (native GHRH) to approximate...
Key claims: Sustained growth hormone elevation; Convenient weekly dosing schedule.
Shop Research Peptides
CJC-1295 DAC 5mg
5mg
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
Semaglutide 10mg
10mg
TB-500 5mg
5mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe